How economics can shape precision medicines

Science

Volumn 355, Issue 6330, 2017, Pages 1131-1133

  Stern, A D ^a,b   Alexander, B M ^c,d   Chandra, A ^a,e,f  

^a HARVARD BUSINESS SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e HARVARD UNIVERSITY   (United States)

^f NATIONAL BUREAU OF ECONOMIC RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BIOSIMILAR AGENT; CHIMERIC ANTIGEN RECEPTOR; ORPHAN DRUG;

BIOMARKER; COMMODITY PRICE; ECONOMETRICS; INCENTIVE; INNOVATION; MEDICINE; PHARMACEUTICAL INDUSTRY; RESEARCH WORK;

COMPETITION; DRUG COST; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; DRUG RESEARCH; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ACCESS; HUMAN; PATENT; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; UNITED STATES; COST; ECONOMICS; HEALTH CARE DELIVERY;

BIOMARKERS; COSTS AND COST ANALYSIS; ECONOMICS; HEALTH SERVICES ACCESSIBILITY; HUMANS; ORPHAN DRUG PRODUCTION; PRECISION MEDICINE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 85015230829     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.aai8707     Document Type: Review

References (19)

1. D. Acemoglu, J. Linn, Q. J. Econ. 119, 1049 (2004).
2. P. Dubois, O. de Mouzon, F. Scott-Morton, P. Seabright, RAND J. Econ. 46, 844 (2015).
3. FDA, Orphan Drug Designations and Approvals Database; www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm.
4. FDA, Novel Drugs Summary (2016); www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm474696.htm.
5. W. Yin, J. Health Econ. 28, 950 (2009).
6. FDA, "Guidance for industry: Expedited programs for serious conditions - Drugs and biologics" (2014); www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm358301.pdf.
7. A. Chandra, J. Vanderpuye-Orgle, JAMA 314, 225 (2015).
8. P. B. Bach, JAMA 312, 1629 (2014).
9. FDA, Guidance for industry (2012); www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm332181.pdf
10. FDA, Laboratory Developed Tests; https://www.fda.gov/medicaldevices/productsandmedicalprocedures/invitrodiagnostics/laboratorydevelopedtests/default.htm.
11. J. H. Cochrane, J. Polit. Econ. 103, 445 (1995).
12. V. Montazerhodjat, D. M. Weinstock, A. W. Lo, Sci. Transl. Med. 8, 327ps6 (2016).
13. The Henry J. Kaiser Family Foundation. The Medicare Part D prescription drug benefit (2016); http://kff.org/medicare/fact-sheet/the-medicare-prescription-drug-benefit-fact-sheet.
14. A. Chandra, A. B. Jena, J. S. Skinner, J. Econ. Perspect. 25, 27 (2011).
15. National Bureau of Economic Research Project on Economic Dimensions of Personalized and Precision Medicine (2017); www.nber.org/callforpapers/EconomicDimensionofPersonalizeandPrecisionMedicine.html.
16. S.M. Berry, J.T. Connor, R.J. Lewis, JAMA 313, 1619 (2015).
17. A. D. Barker et al., Clin. Pharmacol. Ther. 86, 97 (2009).
18. H. S. Rugo et al., N. Engl. J. Med. 375, 23 (2016).
19. J. W. Park et al., New Engl. J. Med. 375, 11 (2016).